Compare TG Therapeutics Inc (TGTX) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Tractor Supply Co — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Tractor Supply Co trades at $34 (market cap $17.72B). The key difference: Tractor Supply Co is far larger — about 2.1× TG Therapeutics Inc's market cap, and Tractor Supply Co pays a 2.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TSCO | |
|---|---|---|
Market Cap | $8.36B | $17.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $60.61 |
52-Week Low | $26.94 | $29.14 |
Enterprise Value | $8.57B | $24.03B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Tractor Supply Company (TSCO) trades at $35.29, up 0.86% today, with a bullish technical signal from moving averages but mixed oscillators. Recent quarterly earnings have missed expectations, though revenue grew to $15.52B in 2025. The company maintains a strong ROE of 39.51% and announced a $0.24 dividend for H2-26. Analyst consensus is split, with a $36.29 price target slightly above the current price.
The outlook is cautiously optimistic given TSCO's solid profitability and strategic initiatives in pet care and logistics, but risks include cyclical sales pressures and margin compression. Upside potential exists if the company meets future earnings estimates and executes its growth plans effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
